Search - tctmd.com

Displaying 161 - 180 of 472

Sort: Relevancy | Date

News Conference News ESC 2020

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

Michael O'Riordan

September 04, 2020

News Conference News ESC 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

L.A. McKeown

September 03, 2020

News Conference News ESC 2020

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Caitlin E. Cox

September 03, 2020

News Daily News

Free CAC Scans for ASCVD Risk Capture More Women, Minorities, and Low-Income Adults

Michael O'Riordan

September 02, 2020

News Industry News

Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral Regurgitation

September 02, 2020

News Opinion CV Team Dispatch

September 2020 News Roundup

L.A. McKeown

September 01, 2020

News Conference News ESC 2020

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

Michael O'Riordan

September 01, 2020

News Conference News ESC 2020

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Yael L. Maxwell

September 01, 2020

News Conference News ESC 2020

Dapagliflozin Wins in Patients With CKD

Todd Neale

August 31, 2020

News Conference News ESC 2020

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

Shelley Wood

August 31, 2020

News Conference News ESC 2020

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

Shelley Wood

August 30, 2020

News Conference News ESC 2020

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Todd Neale

August 30, 2020

News Conference News ESC 2020

Trimetazidine Safe but Not Protective Long-term After PCI

Caitlin E. Cox

August 30, 2020

News Conference News ESC 2020

Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI

Todd Neale

August 30, 2020

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Conference News ESC 2020

More Than Half of Patients See a GP in the 2 Weeks Before OHCA

Yael L. Maxwell

August 28, 2020

News Daily News

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

Michael O'Riordan

August 28, 2020

News Daily News

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

Yael L. Maxwell

August 27, 2020

News Daily News

‘Message Unchanged,’ Say Researchers of Criticized COVID-19 CMR Study

Michael O'Riordan

August 26, 2020

Advertisement

COVID-19 Blamed for Weaker Research Published by Top-Tier Journals in 2020

VOYAGER PAD: CAD Subanalysis Finds Fewer CV, Limb Events With Rivaroxaban

New European NSTE ACS Guidelines Embrace hs-Troponin, CTA, NOAC Trials

Free CAC Scans for ASCVD Risk Capture More Women, Minorities, and Low-Income Adults

Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral Regurgitation

September 2020 News Roundup

ACE Inhibitors, ARBs Pose No Risk in COVID-19: BRACE CORONA

In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD

Dapagliflozin Wins in Patients With CKD

Antihypertensives Cut CV Events Across BP Levels, Regardless of Prior CVD: BPLTTC

Updated ESC A-fib Guidance Proposes New Path for Diagnosis, Classification, and Care

PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF

Trimetazidine Safe but Not Protective Long-term After PCI

Go With Aspirin Alone After TAVR When Anticoagulation Isn’t Needed: POPular TAVI

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

More Than Half of Patients See a GP in the 2 Weeks Before OHCA

Systemic Anticoagulation Linked to Lower Mortality in Hospitalized COVID-19

Icosapent Ethyl Could Prevent Thousands of CVD Events if Used as Indicated

‘Message Unchanged,’ Say Researchers of Criticized COVID-19 CMR Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content